Macular Degeneration Trial, Recruiting NCT00286637 Sponsor: Wills Eye Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT00286637
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study and agree to take part in it
  • Healthy people with no eye or other conditions
  • People who have been diagnosed with age-related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy (a condition affecting the back of the eye), and/or glaucoma or suspected glaucoma
  • For a specific part of the study only: people who have been diagnosed with Alzheimer's disease or mild cognitive impairment (early-stage memory and thinking changes)

Who may not be able to join:

  • People taking certain long-term medications (such as corticosteroids, hydroxychloroquine, chloroquine, thioridazine, or canthaxanthine), or people who have conditions such as stroke that affect vision or the thickness of the retina, apart from glaucoma
  • People who have a squint (eyes that don't align), uncontrolled eye movements (nystagmus), or any condition that makes it difficult to hold a steady gaze
  • People who have cloudiness or other issues inside the eye that block a clear view of the back of the eye, or any non-glaucoma-related eye abnormality inside the eye
  • People who have had an eye injury or eye surgery, other than uncomplicated glaucoma treatment or cataract removal that took place at least 3 months before joining the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joel S Schumann, MD, Wills Eye Hospital

Phone: 215-928-3197

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Wills Eye
Registry
ClinicalTrials.gov
Start date
1 August 2000
Est. completion
31 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants who Show Evidence of Glaucoma Progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov